Summary:
- Scopio Labs, a developer of Full-Field Cell Morphology imaging and analysis platform, raised $10M in Series D extension funding.
- The funding round was led by Viola Growth, bringing the total investment to $52M.
- The company plans to use the funds to expand operations and further develop their technology for improving cell morphology analysis.
Article:
Scopio Labs Secures $10M in Series D Extension Funding
Scopio Labs, a leading developer based in Parsippany, NJ, has recently announced a significant milestone in their growth journey. The company successfully raised $10 million in a Series D extension funding round, with Viola Growth leading the investment efforts. This latest injection of capital brings Scopio Labs’ total funding to an impressive $52 million, signaling strong support and confidence in the company’s innovative approach to Full-Field Cell Morphology imaging and analysis.
Driving Innovation in Cell Morphology Analysis
Under the leadership of CEO Itai Hayut, Scopio Labs is at the forefront of revolutionizing cell morphology analysis. By offering a comprehensive suite of digital imaging and analysis platforms, the company empowers lab scientists and clinicians with advanced tools for early detection and diagnosis of blood-related medical conditions. This not only expedites patients’ access to life-saving treatments but also enhances the overall efficiency and accuracy of diagnostic processes.
Pioneering Technology for Better Patient Outcomes
Scopio Labs’ high-resolution imaging capabilities, combined with embedded artificial intelligence, enable more efficient remote workflow within secure hospital networks. This seamless integration of technology allows for better collaboration among healthcare professionals and contributes to improved diagnostics across the continuum of care. By investing in the expansion of their operations and development efforts, Scopio Labs is poised to make a lasting impact in the field of medical imaging and analysis.
In conclusion, Scopio Labs’ recent funding success underscores the company’s commitment to driving innovation and improving patient outcomes through advanced cell morphology analysis technology. With a strong financial backing and a clear vision for the future, Scopio Labs is well-positioned to lead the way in transforming the landscape of healthcare diagnostics.
Published by FinSMEs on 25/07/2025
